ARCHIVES

Report calls for stronger peer review, prioritization for cancer clinical trials.

This article is from The Cancer Letter archive.

Vol. 31 No. 23 | June 10, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

Did The Dog Eat It? NIH Fails To Turn In A Prostate Cancer Plan Assigned By Senate

April 23, 1999

“Great Charlie Moertel Shootout: In Tucson Draws Laughs, Criticism

April 17, 1981

In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit

December 18, 2009

Rituximab Maintenance Improves Survival In Relapse

February 27, 2009

High-Dose Vitamin D With Docetaxel In Testing For Advanced Prostate Cancer

September 27, 2002